DIVI S LABORATORIES LTD vs LINCOLN PHARMA LTD
A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and LINCOLN PHARMA LTD (LINCOLN) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs LINCOLN on 12 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
Valuation
How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
How efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
- − ["Stock is trading at 10.8 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
- + ["Company is almost debt free."]
- − ["The company has delivered a poor sales growth of 9.61% over past five years.", "Company has a low return on equity of 13.8% over last 3 years.", "Earnings include an other income of Rs.33.4 Cr.", "Dividend payout has been low at 4.11% of profits over last 3 years", "Working capital days have increased from 159 days to 239 days"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.